Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nab-paclitaxel + Carboplatin + Endostatin vs Paclitaxel + Carboplatin in Advanced Melanoma
NCT03917069Phase 2Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Mar 2019
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in melanoma comparing nab-paclitaxel + endostatin + carboplatin with paclitaxel + carboplatin (2 arms). Primary endpoint: Progression Free Survival at 3 years. Status: unknown.
02
Drugs
endostarpaclitaxel
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT03917069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03917069.